Vaccine Damage Xrays from Myocarditis by Vaccine Manufacturer

 


Comments

Post a Comment

Popular posts from this blog

The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147-receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease

  bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.423721 ; this version posted July 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Original research article The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147-receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease Elisa Avolio, PhD 1 ; Michele Carrabba, PhD 1 ; Rachel Milligan, PhD 2 ; Maia Kavanagh Williamson, PhD 2 ; Antonio P Beltrami, MD PhD 3 ; Kapil Gupta, PhD 4 ; Karen T Elvers, PhD 5 ; Monica Gamez, PhD 1 ; Rebecca Foster, PhD 1 ; Kathleen Gillespie, PhD 1 ; Fergus Hamilton, PhD 1 ; David Arnold, PhD 1 ; Imre Berger, PhD 4,6 ; Massimo Caputo, MD 1 ; Andrew D Davidson, PhD 2 ; Darryl Hill, PhD 2 ; Paolo Madeddu, MD 1 (1) Bristol Medical School, Translational Health...
Read more

A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products

A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products 10/07/2021 Web Internet Archive Capture Abstract Following the global rollout and administration of the Pfizer Inc./BioNTech BNT162b2 and Moderna mRNA-1273 vaccines on December 17, 2020, in the United States, and of the Janssen Ad26.COV2.S product on April 1st, 2021, in an unprecedented manner, hundreds of thousands of individuals have reported adverse events (AEs) using the Vaccine Adverse Events Reports System (VAERS). We used VAERS data to examine cardiac AEs, primarily myocarditis, reported following injection of the first or second dose of the COVID-19 injectable products. Myocarditis rates reported in VAERS were significantly higher in youths between the ages of 13 to 23 (p
Read more